arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT US Pharma and Biotech Summit

Securing the Future: Disrupting the Pharma Business Model

New York |
Speakers include:
Amy  Abernethy

Amy Abernethy

U.S. Food & Drug Administration (FDA)

Kabir Nath

Kabir Nath

Otsuka

Jack  Bailey

Jack Bailey

GlaxoSmithKline

Overview

Join us for the annual FT US Pharma and Biotech Summit on May 14, 2019 as our distinguished line-up of industry leaders and experts assemble to share insights and perspectives on the critical issues set to re-shape the sector - from the increasingly complex and uncertain political and pricing environment and the arrival of CAR-T to the rise of digital therapeutics.

fallback
fallback Add to my Calendar 05/14/2019 08:00:0005/14/2019 17:30:00trueFT US Pharma and Biotech SummitJoin us for the annual FT US Pharma and Biotech Summit on May 14, 2019 as our distinguished line-up of industry leaders and experts assemble to share insights and perspectives on the critical issues set to re-shape the sector - from the increasingly complex and uncertain political and pricing environment and the arrival of CAR-T to the rise of digital therapeutics.FT-US-Pharma-and-Biotech-Summit69a47e6bc8dbbea577722ba1d9f8f802MM/DD/YYYY

Read the FT

fallback

Full Overview

The disruption which has become a feature of the pharma landscape in recent years show no signs of slowing pace. The advent of the new wave of advanced cell and gene therapies will move pharma further in the direction of high specialized and personalized drug development. At the same time, pharma must find a way to win in the burgeoning business of disease management, prevention and improved patient outcomes if it is to secure its place in the increasingly value-oriented healthcare world. What are the strategies pharma companies can employ to protect profitability as the competitive landscape continues to evolve?

fallback

Speakers (26)

Amy  Abernethy

Amy Abernethy

Principal Deputy Commissioner
U.S. Food & Drug Administration (FDA)
Kabir Nath

Kabir Nath

President, North America Pharmaceuticals
Otsuka

Kabir is a senior commercial leader with more than 25 years of broad international biopharma and devices experience who has shaped strategy and delivered results in complex, challenging business environments at country, regional and global levels. He has lived and worked in the UK, France, Spain, India, Singapore, China and the US. Kabir joined Otsuka to head the North American pharmaceutical business in 2016, with direct responsibility for Otsuka America Pharmaceuticals, Inc., Avanir and Otsuka Canada. Before joining Otsuka, Kabir spent 13 years in leadership roles at Bristol-Myers Squibb(BMS). Most recently he was Senior Vice President, Virology, Transplant & Optimized Brands, responsible for the commercialization of a significant portfolio – including drugs for HIV, hepatitis B and hepatitis C and immunosuppression in the USA. Previously he was Senior Vice President, Global Commercialization Virology & Neuroscience, leading global strategy for these two disease areas. In addition, he served as interim head of Emerging Markets for much of 2012. Kabir joined BMS in Singapore in 2003 as Vice President for South East Asia/ Taiwan/HK and moved to Shanghai in 2005 as president of BMS China. In 2008, Kabir was appointed President, Asia Pacific Medicines, with responsibility for all commercial operations in 13 countries. Prior to joining BMS, Kabir spent 11 years at Smith & Nephew, the medical technology company, in senior operational and strategic roles in the UK, Europe and Asia. Kabir holds an MA from King’s College, University of Cambridge, and an MBA with Distinction from INSEAD.

Jack  Bailey

Jack Bailey

President US Pharmaceuticals
GlaxoSmithKline
Johanna Mercier

Johanna Mercier

President and Head of U.S. & Large Markets
Bristol-Myers Squibb

Johanna Mercier is President and Head of US & France, Germany, Japan/Korea/Taiwan at Bristol-Myers Squibb. In this leadership role, she strives to instill a balance of innovation and accountability among the 4,500 employees working to deliver transformational medicines from the company’s oncology, cardiovascular, and immunoscience portfolios. Ms Mercier is also actively engaged with the policy and advocacy community to ensure the affordability and access of prescription medicines to patients. Her career at Bristol-Myers Squibb spans 25 years. After over a decade in sales and marketing in Canada, she went on to lead worldwide early and clinical portfolios followed by market teams across both the US and Europe.  As General Manager of UK & Ireland, Ms Mercier achieved double digit growth while implementing a new operating model. As President of Worldwide Markets for Europe, Australia and Canada, she led international markets driving $4B in revenue and overseeing 1700 employees.  She successfully attained access and reimbursement in the region for the company’s immuno-oncology portfolio in highly cost-sensitive markets. She most recently led the US business and successfully evolved the culture and drove strong commercial execution with double digit growth and multiple launches that changed the standard of care in melanoma and renal cancers. Ms Mercier is a director on the Robert Wood Johnson University Hospital Board. She is a staunch advocate for diversity and inclusion and a sought-after mentor. She holds a science degree from the University of Montreal, and an MBA from Concordia University.

Barbara Tardiff

Barbara Tardiff

Head, Bioinformatics
Verily Life Sciences

Barbara Tardiff is currently Head Bioinformatics at Verily Life Sciences LLC. Over the course of her career she has participated in a broad range of scientific and operational activities related to medical product development including protocol design, project leadership and administration, data management, information systems, and interpretation and presentation of study findings. She participated as a charter member of the Steering Committee for the Clinical Trial Transformation Initiative (CTTI), a collaboration between the FDA and Duke University directed at improving the quality and efficiency of clinical trials and has been active in establishing standards through the Clinical Data Interchange Standards Consortium (CDISC) and Health Level Seven (HL7). Dr Tardiff’s educational background includes training in medicine, clinical research, information management, business administration, and cellular and molecular biology and biochemistry. She is Board certified in both Pediatrics and Anesthesiology with subspecialty training in cardiothoracic anesthesia. She completed a clinical research fellowship at the Duke Clinical Research Institute (DCRI).

Martin VanTrieste

Martin VanTrieste

President and CEO
Civica Rx

Martin VanTrieste is a former chief quality officer at Amgen who was recently named the #2 leader on The Medicine Maker’s Power List of Industry Influencers. He brings over 35 years in the industry, with comprehensive experience in biopharmaceutical manufacturing, quality systems and related government regulations in the US and around the world.  

Prior to joining Amgen, Mr. VanTrieste was with Bayer Healthcare’s Biological Products Division as vice president of worldwide quality and Abbott Laboratories as the vice president of quality assurance for the Hospital Products Division.

Mr. VanTrieste is the founder of Rx-360, an international nonprofit organization that enhances patient safety by increasing security and quality in the biopharmaceutical supply chain. He has also served as the Chairman of the Parenteral Drug Association (PDA) Board of Directors.

Mr. VanTrieste earned a Pharmacy degree from Temple University School of Pharmacy.

Corey McCann

Corey McCann

President and CEO
Pear Therapeutics

Corey M. McCann M.D., Ph.D. is the President and CEO of Pear Therapeutics. Previously, Dr McCann was an investor with MPM Capital, where he evaluated new healthcare investment opportunities, managed relationships with strategic partners, and oversaw strategy and execution at portfolio companies. Prior to MPM, he was an Engagement Manager with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He is also a co-founder, advisor, or Board Director at AgNovos Healthcare, Alcyone Lifesciences, Dragonfly Sciences, Edumedics, Resolute Bio, Selexys Pharmaceuticals, and Zillion Health. For his PhD, Dr McCann studied the molecular biology of synapses at Harvard University and at Washington University in St Louis. He was also a post-doctoral researcher at the Massachusetts General Hospital where he developed imaging techniques for the visualization of the brain. He received his MD from Washington University in St. Louis. He graduated summa cum laude from The Pennsylvania State University where he was an Evan Pugh Scholar, receiving a BS in Biology with minors in neuroscience, biochemistry, and molecular biology.

Neal Batra

Neal Batra

Healthcare Strategy Partner
Deloitte

Neal is a New York-based Partner of Deloitte focused on healthcare strategy.  He serves clients across the healthcare ecosystem on strategy challenges related to business model and operating model transformation.  Neal is a co-author of Deloitte’s Future of Health (2040) point-of-view, which outlines the breakdown of the current industry structure and the emergence of a new healthcare ecosystem oriented around next-gen value drivers.  He is a leader in Deloitte’s Strategy & Analytics practice as well as the firm’s Life Sciences Strategy Lead.  He has over 15 years of experience advising leading healthcare organizations on issues related to digital transformation, growth & innovation, next-gen business models and business unit / enterprise strategy.   Neal holds his MBA from London Business School and a BBA from the College of William & Mary. 

Paul Bleicher

Paul Bleicher

CEO
OptumLabs

Paul Bleicher, MD, PhD, is the CEO of OptumLabs, an open, collaborative research and innovation center established by Mayo Clinic and Optum to accelerate improvements in patient care and value through clinical, policy and product innovation driven by new insights from healthcare big data.  Previously, he was Chief Medical Officer for Humedica, a next-generation clinical informatics company. Before Humedica, Dr Bleicher was a founder of, and spent 11 years building and guiding the growth of Phase Forward, which led the transformation of pharmaceutical clinical trials from paper to the web, and was acquired by Oracle in 2010. He began his career as a dermatologist/researcher at Massachusetts General Hospital/Harvard Medical School, and subsequently worked in clinical development in the biopharmaceutical industry.

Rena Conti

Rena Conti

Associate Professor, Markets, Public Policy and Law
Questrom School of Business, Boston University
Richie Etwaru

Richie Etwaru

Human Data Ethicist & CEO
Hu-Manity.co

Richie Etwaru believes the most important ingredient for change is courage. Courage not mistaken with risk but consistent with the bravery required to embark upon something never attempted.  Mr Etwaru has spanned unlikely disciplines and multiple continents over two decades. He has had the honor to operate in academia, entrepreneurship, government advisory, and Fortune 500 companies in financial services and healthcare. He’s been quoted in NPR, The Wall Street Journal, The Financial Times, The Washington Post, Computer World, Forbes, VentureBeat, WIRED, and has appeared on dozens of television stations and media outlets globally.  As founder and CEO of Hu-manity.co, Mr Etwaru is known for pursuing the 31st Human Right “everyone has the right to legal ownership of their inherent human data as property.” He is driven to reshape the world by creating a new data economy, where inherent human data is legally human property.

Jessica Federer.

Jessica Federer.

Advisor
Hugo Health

Recognized as one of the top 100 global Chief Digital Officers (CDOs), a "Power-Lady" of the German economy, and a leading Health Tech Influencer, Jessica Federer is adept at translating digital developments into meaningful advancements for both business and society. After serving as the Chief Digital Officer for Bayer, Jessica is now an advisor for health and technology companies, and a Venture Affiliate Partner at Boston Millennia Partners. Prior to leading digital at Bayer, Federer held positions in Global Regulatory Affairs, Market Access, Communications and Public Affairs. She also served on the United Nations m-Powering Development Advisory Board for the Agency for Information and Communications Technology (ITU). Jessica began her public health career as an analyst at the Agency for Healthcare Research and Quality in the US Department of Health and Human Services. She earned a Bachelor of Science degree from the George Washington University, and a Master of Public Health from Yale.

Vipin Gopal

Vipin Gopal

Chief Data and Analytics Officer
Eli Lilly

Vipin Gopal, PhD, MBA, is the Chief Data and Analytics Officer at Eli Lilly, which he joined in early 2018. In this role, he is responsible for the enterprise strategy and development of advanced analytics and data science solutions. Dr Gopal is a 20-year veteran in the space of advanced data and analytics, and has a significant track record of building high-performance analytics functions and creating business value with advanced analytic technologies . His leadership experience spans four Fortune 100 companies in industries ranging from healthcare to aerospace . Before joining Eli Lilly, Dr Gopal was the Senior Vice President of Clinical Analytics at Humana, where he was responsible for the corporate organization that developed and applied data science and analytics solutions to advance Humana’s clinical strategy, operations , quality and outcomes. Prior to Humana, he was with Cigna Healthcare , United Technologies Corporation and Honeywell. Dr Gopal obtained his doctorate from Carnegie Mellon University and B. Tech. from the Indian Institute of Technology (IIT), Bombay, both in engineering, and has an MBA from the New York University Stern School of Business. In recognition of his leadership contributions in the space of data and analytics, he was listed as a ‘2018 Top 100 Innovator in Data and Analytics’ and was awarded the 2015 Analytics Leadership Award by Indiana University Kelly School of Business. Dr. Gopal has served anizing/advisory committees of many national and international analytic conferences, and is a frequent speaker on the transformational power of advanced analytics for a broad range of strategic topics in healthcare. Dr Gopal is a passionate advocate of educational initiatives and developing an empowered and diverse workforce. Most recently, he served as a cosponsor of Humana Asian and Pacific Islander (HAPI) Network Resource Group, Chair of the Advisory Board of Greater Louisville International Professionals (GLIP), and as a member of the Board of Directors of Jefferson Community and Technical College (JCTC) Foundation

Peter  Hames

Peter Hames

Co-founder and CEO
Big Health

Peter Hames is CEO of Big Health, a digital medicine company he co-fueled founded with clinical psychologist Professor Colin Espie (University of Oxford). Big Health creates automated behavioral medicine programmes fuelled by tracked data, and was inspired by Mr Hames's difficulty in getting access to evidence ­based non­-drug solutions to his own insomnia.

Joseph La Barge

Joseph La Barge

Chief Legal Officer
Spark Therapeutics

Joseph La Barge is a seasoned executive and legal advisor with more than 15 years of experience counseling life science companies and healthcare institutions. Before joining Spark Therapeutics, Mr La Barge was Vice President, General Counsel and Chief Compliance Officer at Tengion, Inc., a clinical-stage regenerative medicine company, where he oversaw legal affairs, compliance and quality assurance. While at Tengion, Mr La Barge helped lead the company’s initial public offering in 2010. He also played an integral role in developing Tengion’s intellectual property strategies for their novel, first-in-class, cell-based therapies.

Dr. David Lennon

Dr. David Lennon

President
AveXis

David Lennon is President of AveXis. Prior to this position, he was with Novartis Oncology, here he served as General Manager, Japan overseeing Novartis’ extensive portfolio in cancer, including hematology, solid tumours and cell and gene therapies. Prior to his role in Japan, he served as Vice President US Solid Tumours Franchise. Before moving to Oncology, David served in the Pharmaceuticals division, where he held leadership positions in roles of increasing responsibility, including global therapeutic head positions and sales & marketing operating roles in US. He has extensive experience in neuroscience, immunology, cardiovascular and rare diseases, and in his final role in this division, served as Chief Marketing Officer, Greater China Region. Prior to joining Novartis, he previously worked as an Associate Principal at McKinsey & Company in New York. David holds a BA.in Biophysics from Columbia University and a PhD. in Cell Biology from Weill Medical College at Cornell University.

Pierre Leurent

Pierre Leurent

Founder and CEO
Voluntis

Pierre Leurent, CEO and Founder of Volluntis has 20 years of experience in digital health in the United States and Europe. Voluntis’ mission is to improve the real-world value of therapies by providing patients and clinicians with digital therapeutics. Its clinical-grade, regulatory-cleared mobile and cloud solutions embed advanced real-time decision support algorithms to enable patients to better manage their treatment in remote collaboration with their healthcare team. Prior to starting Voluntis in 2001, Mr Leurent worked at GE Medical Systems, where he took part in the development of medical imaging software. He also occupied several positions at HealthCenter Internet Services, a San Francisco-based vendor of electronic medical record solutions. Mr Leurent is a founding member of the Digital Therapeutics Alliance, of which he serves as first Chairman. He also co-chairs the digital therapeutics task force of the Personal Connected Health Alliance (member of HIMSS), and he is the Chairman of the eHealth France Alliance.  He is a graduate of the Ecole Centrale Paris engineering school.

George McMillan

George McMillan

Chief Commercial Officer
ICON

George McMillan is Chief Commercial Officer of ICON, a position he has held since 2017. He joined ICON in 2012 as Executive Vice President of Finance Operations. Prior to ICON, George held senior executive positions in a variety of service and consulting companies, most recently as CFO of PharmaNet Development Group. He also served as CEO of Palladium Group, a global leader in corporate performance management software and consulting; CFO and CEO of CMGI, the internet holding company, for which he was named Mass HighTech Turnaround CEO of the Year. George was also CEO of BMG Direct, the North American music distribution division of Bertelsmann, A.G., and CFO/COO of Renaissance Solutions, a strategic consulting and technology services company. George holds a Bachelor of Arts degree in Economics from Stanford University, a Doctor of Law from Harvard Law School and a Masters of Business Administration from Harvard Business School.

David  Mitchell

David Mitchell

Founder
Patients For Affordable Drugs

David Mitchell has an incurable blood cancer called multiple myeloma and requires more than $325,000 in drugs to survive. Like millions of others, Mr Mitchell needs innovation and new drugs for his survival, but he believes drugs don’t work if people can’t afford them. After more than 30 years at a D.C. policy communications firm, he retired in December 2016 to devote his full energy to helping change policy to lower prescription drug prices. Patients For Affordable Drugs mobilizes patients and allies at the federal and state levels and does not accept funding from any organizations that profit from the development or distribution of prescription drugs.

Heather Preston

Heather Preston

Managing Partner
Pivotal BioVenture Partners

Heather Preston MD joined Pivotal in 2018 and brings 30 years of healthcare experience. Most recently she was a Firm Partner and Managing Director at TPG Biotech and she is currently a Senior Advisor to TPG.  Prior to joining TPG in 2005, Dr Preston spent two years investing with JP Morgan Partners and she was also an Entrepreneur-in-Residence with New Enterprise Associates. Prior to becoming a venture capital investor, Heather spent five years at McKinsey & Co. in New York, where she was a leader of their pharmaceutical and medical products consulting practice.  She advised large pharmaceutical companies and biotechnology companies on critical strategic issues such as R&D portfolio prioritization, M&A opportunities, new technology acquisitions, new product launches and product growth strategies. Dr Preston currently serves on the board of directors of Oxford Biomedica (LSE:OXB); Alder BioPharmaceuticals (NASDAQ:ALDR); Otonomy, Inc. (NASDAQ:OTIC); Unchained Labs, Avalyn Pharmaceuticals, Azura Opthalmics and Entasis Inc. She has previously served on multiple boards including  Albireo (NASDAQ:ALBO), Aptalis Pharma (acquired by Forest Labs in 2014), and Elevation Pharmaceuticals (acquired by Sunovion in 2012). She was responsible for TPG Biotech’s investment in Par Pharmaceuticals (acquired by Endo Pharmaceuticals in 2015). She has an undergraduate degree in biochemistry from the University of London and a medical degree from the University of Oxford. She completed a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University and trained in Internal Medicine at the Massachusetts General Hospital, Harvard and sub-specialized in Gastroenterology and Hepatology at UCSF.  During her academic medical career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-doctoral Fellowship Award. Dr Preston also serves on the Board of Trustees for the Harvard Discovery Council, the Fine Arts Museums of San Francisco, Saint Luke’s School and the Harlech Scholarship Foundation.

Michael Ryan

Michael Ryan

Senior Vice President, Worldwide Value, Access, Policy and Health Economics and Outcomes Research
Bristol-Myers Squibb
Michael Sherman

Michael Sherman

Senior Vice President, Chief Medical Officer
Harvard Pilgrim Health Care

Michael Sherman serves as Chief Medical Officer and Senior Vice President for Harvard Pilgrim Health Care. Dr Sherman has been a leader in driving adoption of outcomes-based provider and pharmaceutical contracts, and is responsible for Harvard Pilgrim’s medical trend management, provider engagement strategy, medical informatics, wellness and health promotion initiatives, care and disease management services, pharmacy services, NCQA accreditation and quality and utilization management programs. He serves on the faculty of Harvard Medical School’s Department of Population Medicine, as Chair of the board of managers of the Harvard Pilgrim Health Care Institute, on the advisory board of the Institute for Clinical and Economic Review (ICER), and on the board of directors for the Personalized Medicine Coalition. Dr Sherman also is the current Chair for AHIP’s CMO Leadership Council, comprising Chief Medical Officers from health plans throughout the United States. Prior to joining Harvard Pilgrim, Dr Sherman held leadership roles at Humana, UnitedHealth Group, and Thomson Medstat (now IBM Truven). He holds a BA and an MS in Biomedical Anthropology from the University of Pennsylvania and received his MD from Yale and MBA from the Harvard Business School.

Julie Schiffman

Julie Schiffman

Vice President of Customer Analytics
Pfizer
Jeffrey Schwartz

Jeffrey Schwartz

Managing Director, Life Sciences
Bain Capital

Jeffrey Schwartz joined Bain Capital in 2004 and is a Managing Director.  Prior to his current role, he was a member of Bain Capital’s Private Equity team, where he focused on healthcare investments. Prior to joining Bain Capital, Mr Schwartz served as an Equity Research Analyst at Lehman Brothers, where he was focused on the aerospace and defence industries working in both New York and London. Mr Schwartz received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar and he graduated magna cum laude from Yale University with a BA in Economics.

Bill Sibold

Bill Sibold

Executive Vice President
Sanofi Genzyme

Bill Sibold holds an MBA from Harvard Business School and a BA in Molecular Biophysics and Biochemistry from Yale University.  He has more than twenty-five years of experience in the biopharmaceutical industry since starting his career with Eli Lilly. He held a number of leadership positions within Biogen, including driving their U.S. commercial operations in neurology, oncology and rheumatology and general management of Biogen’s Australian and Asia-Pacific business. In addition to his time with Biogen, Mr Sibold also served as the Chief Commercial Officer of Avanir Pharmaceuticals.  Bill Sibold joined Sanofi in late 2011 as head of the MS franchise where he oversaw the successful launches of Aubagio® and Lemtrada®. He most recently served as head of Sanofi Genzyme’s Global Multiple Sclerosis, Oncology and Immunology organization, a position he held since January 2016 and where he led preparation for the global launches of Dupilumab and Sarilumab. He was appointed to his present position in July 2017.

 Alex  Zhavoronkov

Alex Zhavoronkov

CEO
Insilico Medicine

Dr. Alex Zhavoronkov is the CEO of Insilico Medicine, a Baltimore-based leader in the next-generation artificial intelligence and blockchain technologies for drug discovery, biomarker development, and aging research. At Insilico, he pioneered the applications of generative adversarial networks and reinforcement learning techniques for generating the novel molecular structures with the desired properties. He set up R&D centres in six countries including Korea, Russia, and Taiwan and launched multiple biomarker initiatives including Young.AI. Previously, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI and established AgeNet.net competitions and Diversity.AI initiative. Since 2012 he has published over 80 peer-reviewed research papers and books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy”.  He is also the co-organizer of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at EMBO/Basel Life, one of Europe's largest industry events in drug discovery. Dr. Zhavoronkov holds two Bachelor degrees from Queen’s University, a Master’s in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University.

fallback

Moderators (3)

Sarah  Neville

Sarah Neville

Global Pharmaceuticals Editor
Financial Times

Sarah Neville began her career on local and regional newspapers, eventually becoming political editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. She joined the Financial Times in 2001 and has since held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and public policy editor in 2011. She was appointed Pharmaceuticals Correspondent in 2016.

Hannah Kuchler

Hannah Kuchler

Financial Times

Hannah Kuchler is US Pharma and Biotech Correspondent for the Financial Times, with a particular focus on how technology is transforming healthcare. She is based in San Francisco.  For five years, Ms Kuchler served as FT’s San Francisco Correspondent where she covered Silicon Valley and technology with a focus on social media and cyber security. Ms Kuchler was previously a London-based UK news reporter for the FT, covering British politics and general UK news. Prior to this, she worked on the FT’s newsdesk, as Asia Correspondent for FT Tilt in Hong Kong, and covered US markets in New York.  Before joining the FT in 2009, Ms Kuchler was the Editor of The Oxford Student and won the Guardian’s Student Reporter of the Year award in 2008. She holds a Bachelor’s degree in Modern History from Balliol College, Oxford.

Greg Reh

Greg Reh

Global Life Sciences & Health Care Industry Leader
Deloitte

Greg Reh is a Global Life Sciences & Health Care Industry Leader and the Global Life Sciences Sector Leader for Deloitte Touche Tohmatsu Limited (Deloitte). He is also the life sciences sector leader for Deloitte in the United States. He has more than 25 years of experience in the life sciences, process manufacturing, consumer and government sectors. His consulting career has spanned such topics as technology strategy, integration solution development and implementation of emerging and disruptive technology. His clients have included multinational pharmaceutical, biotechnology and chemical manufacturing organizations where he successfully led consulting services in support of regulatory, clinical, commercialization and manufacturing operations.

Prior to his consulting career Greg held positions at a government research lab, where he led teams in the design and development of life support devices; and was a lecturer at the University of Pennsylvania.

Advisory Board (7)

Rajni Aneja

Rajni Aneja

Connection Science Fellow
MIT Connection Science

Rajni Aneja is an MIT Connection Science Fellow, health care strategist, public speaker, transformative change agent with expertise in population health management and digital health. She serves as an advisor to variety of health and wellness organisations. Dr Aneja encompasses various vantage points as a clinician, executive, advisor, entrepreneur, speaker and technology advocate serving in senior leadership roles to include Chief Medical Officer for WebMD health, EVP of Joslin and strategic executive, transformation leader at Humana and most recently contributed to the builing of a digital consumer strategy at Novartis. Dr Aneja is spreading the vision for strategy and innovation across different spectrums of health care Dr. Aneja received her MD from Research Medical Center in Kansas City and MBA from University of Massachusetts.

Kim  Boericke

Kim Boericke

Executive Vice President, Program Management
ICON

Kim Boericke has been leading Global Program Management for ICON since 2014. In this role, she heads the company’s therapeutic units (Oncology, Cardiovascular/Metabolic Diseases, CNS and Aging Diseases, Rare Diseases, Infectious Disease and Vaccines, Internal Medicine and Immunosciences, and Biosimilars). These units contain the project management and clinical trial management teams. In addition, she has responsibility for the trial support teams (Clinical Trial Associates, Project Resourcing, Trip Report Reviewer and the Project Management Office). The goal of Global Program Management is to deliver on projects, programs and portfolios, expand the various partnerships and ensure programs are delivered on time and with the quality expected. She is also accountable and responsible for the P&L, while her team is focused on operational delivery and expansion of our customer relationships. Through her experiences, Ms Boericke has gained expertise in managing global drug development programs through all clinical phases (I – IV) including ISS/ISE analyses, developing strong customer management programs and managing global operations. Prior to joining ICON, Ms Boericke worked her way up, over twenty plus years, from project to senior management roles across various CROs (Quintiles, INC
Research, Duke Clinical Research Institute, i3). Earlier in her career, in 1996, Ms Boericke managed global drug development programs for a clinical research organization (CRO), ClinTrials., and prior to that, from 1992, Ms Boericke was with Becton Dickinson Research Center where she led the biological models team conducting preclinical and first in human research for the transdermal drug delivery division. Ms Boericke started conducting basic preclinical research at Duke University in 1989.

Rowan Chapman

Rowan Chapman

Head
J&J Innovation
Adam Gluck

Adam Gluck

Head of US External Affairs
Sanofi
Leslie Krumholz

Leslie Krumholz

CEO
Hugo Health

Leslie Krumholz is a social entrepreneur dedicated to improving lives through technology. As the CEO of Hugo Health, a transformative new technology radically changing how information is collected and shared for clinical research. Ms Krumholz is working with industry leaders to redefine what it means to engage people as partners in research, while powering faster, more efficient and more affordable innovation. Of the three inaugural demonstration projects, for the FDA’s National Evaluation System for Health Technology (NEST), two included Hugo Health. Prior to co-founding Hugo Health, Ms Krumholz was CEO of GoodStreets, one of Connecticut’s first Benefit Corporations and a “Connecticut Tech Company to Watch”. She is a recipient of the reSET Social Enterprise Award and a Connecticut Tech Council Women of Innovation Honoree. Ms Krumholz has a BA from the University of Massachusetts/Amherst and a JD from the University of California, Hastings College of Law.

Michael  Rea

Michael Rea

Founder and CEO
Rx Savings Solutions

Michael Rea founded Rx Savings Solutions in 2008 after routinely witnessing consumers struggling to pay for their medications. He noticed quickly at that time that consumers were paying much more than they needed to, which was attributable to a lack of information available to them. He set out on his mission to arm consumers with this information and add efficiency and transparency back into the world of pharmacy. Dr Rea has been involved with research surrounding pharmacy transparency for over 10 years. He received his Doctor of Pharmacy degree from Creighton University.

Greg Reh

Greg Reh

Global Life Sciences & Health Care Industry Leader
Deloitte

Greg Reh is a Global Life Sciences & Health Care Industry Leader and the Global Life Sciences Sector Leader for Deloitte Touche Tohmatsu Limited (Deloitte). He is also the life sciences sector leader for Deloitte in the United States. He has more than 25 years of experience in the life sciences, process manufacturing, consumer and government sectors. His consulting career has spanned such topics as technology strategy, integration solution development and implementation of emerging and disruptive technology. His clients have included multinational pharmaceutical, biotechnology and chemical manufacturing organizations where he successfully led consulting services in support of regulatory, clinical, commercialization and manufacturing operations.

Prior to his consulting career Greg held positions at a government research lab, where he led teams in the design and development of life support devices; and was a lecturer at the University of Pennsylvania.

fallback

Agenda - 14th May

  • 8:00am
    Registration and networking
  • 9:00am
    Opening remarks from the chair

    Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 9:05am
    Keynote address
  • 9:20am
    Panel: Drug pricing in the US - the road to 2020

    Drug pricing remains a headline issue in the US and the President has set his sights firmly set on the pharma industry with his Blueprint to overhaul drug prices and cut out of pocket expenses for patients. The proposed measures aim to ‘change the way drugs and delivered and paid for in the US’, through ‘an unprecedented re-examination of the whole system’ and the exploration of ‘new disruptive alternatives to the current system’. Will the Action Plan come to pass? What are the prospects for bipartisan action on pricing? Will Democrats push for a single payer system? How much of the Action plan is bold and what is bluster? Will the measures succeed in lowering drug prices? Are rebates a force for good or bad, and what could replace them? Without rebates, would prices rise as pharma companies wield their pricing power across a now fragmented payer landscape, or compete to lower prices? How can the current system of incentives be reformed to lower costs? What lies ahead for drug pricing in the US?

    Rena Conti, Associate Professor, Markets, Public Policy and Law, Associate Research Director, Institute for Health System Innovation & Policy, Questrom School of Business, Boston University
    Michael Sherman, Chief Medical Officer and Senior Vice President for Health Services, Harvard Pilgrim Health Care
    David Mitchell, Founder, Patients For Affordable Drugs
    Michael Ryan, SVP, Worldwide Value, Access, Policy and Health Economics and Outcomes Research, Bristol-Myers Squibb

    Moderator:  Hannah Kuchler, Financial Times

  • 10:05am
    Keynote

    Bill Sibold, Executive Vice President, Sanofi Genzyme

  • 10:20am
    Panel: Delivering on the potential of personalized medicine: Advanced cell and gene therapies

    A new generation of potentially curative therapies for some of our deadliest cancers and intractable diseases are gaining approval and can be expected to make their way to patients in the year ahead. The emergence of these highly personalized therapies will be transformative for healthcare systems, for pharma companies and for patients - not only in terms of their potential to extend and save lives, but also in how we pay for them, and the infrastructure we will need to deliver them. What are the challenges in bringing these advanced cell and gene therapies to patients? What health system innovation will be needed, and how can clinical adoption by physicians and healthcare systems be encouraged? What patient engagement strategies will be needed? How do you democratize access - what are the innovative payment models to enable this? How will pharma adjust its commercial and operating model to account for the expected growth of these personal treatments in the years ahead, and is the level of personalization they entail a sustainable business model for pharma? 

    Joseph La Barge, Chief Legal Officer, Spark Therapeutics  
    David Lennon, President, Avexis
    Alberto Santagostino, Senior Vice President-Head of Cell and Gene Technology, Lonza
    Moderator: Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte

  • 11:05am
    Networking coffee break
  • 11:25am
    Keynote address/presentation

    George McMillan, Chief Commercial Officer, ICON 

  • 11:40am
    Securing the future: Disrupting the pharma business model

    From hospital collaboration in generics and gene testing companies conducting clinical trials, to a new wave of digital disruptors chipping away at pharma value chain, pharmaceutical companies face competition in every part of their business. Meanwhile the industry is being pulled in two seemingly countervailing directions - through a one-to-few business model increasingly focused on specialization and custom drugs on the one hand, and the commercial necessity of building one-to-many business models focused on patient outcomes, disease management and prevention on the other.

    • Is population health management (PHM) a threat or an opportunity for pharma, and how can pharma play in this space? Can pharma make a business out of prevention?
    • Will we see players in the currently fragmented PHM (‘emerging platform of care’) space coalesce into major health brands?
    • With the growing firepower of big tech invested in health, will we see tech-pharma mergers in the future?
    • As incursions of new players shatter the pharma status quo, what are the growth strategies pharma companies can employ to preserve to protect market profitability and maintain industry competitiveness?
    • What does the disintermediation of the physician mean for pharma?
    • What is the next big area of pharma business ripe for disruption?

    Session Keynote: Jack Bailey, President, US Pharmaceuticals, GlaxoSmithKline
    Martin VanTrieste, President and CEO, Civica RX
    Johanna Mercier, President and Head of U.S. & Large Markets, Bristol-Myers Squibb
    Neal Batra, Life Sciences & Health Care Strategy Principal, Deloitte
    Barbara Tardiff, Head, Bioinformatics, Verily Life Sciences
    Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 12:30pm
    Lunch
  • 1:30pm
    Panel: Digital therapeutics: Competition or collaboration?

    A new generation of digital therapeutics that rely on software as a key component in managing or curing a disease are catching the attention of healthcare systems looking to cope with rising numbers of patients. Combining scientific rigor and the ingenuity of the tech industry, these new digital interventions have also caught the attention of pharma companies looking to opportunities to partner or invest. What is the potential market for these new digital interventions? Will we see digital therapeutics become a mainstream part of prescribing? Will payers pay? How much will they cost? Will they be reimbursed for their medical value ‘just like a drug’? Should pharma fear, or look to partner with these new players?

    Kabir Nath, President, North America Pharmaceuticals, Otsuka
    Peter Hames, Co-Founder and CEO, Big Health
    Pierre Leurent, Chief Executive Officer, Voluntis
    Corey McCann, President and CEO, Pear Therapeutics
    Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 2:20pm
    Panel: A new era of patient-owned data: What does it mean for pharma?

    As patients increasingly become the owners of their own genomic and general health data, what does it mean for pharma and for the balance of power between pharma and the patient? Will patients be willing to share the data, and should/will they be paid for it? Will it lead to new models of drug development? Will patient create data commons around disease areas increasingly dictating the focus and direction of drug development?

    Session Keynote: Richie Etwaru, Founder and Chief Executive Officer, Hu-manity.co
    Jessica Federer, Advisor, Hugo Health
    Amy Abernethy, Principal Deputy Commissioner, U.S. Food & Drug Administration (FDA)
    ModeratorSarah Neville, Global Pharmaceuticals Editor, Financial Times 

  • 3:05pm
    Keynote
  • 3:20pm
    Panel: Advances in analytics: Applications at the heart of pharma

    The burgeoning field of AI is attracting increasing amounts of investment from pharma companies who are putting their faith in the technology’s ability to drive the next big leaps in drug development and diagnostics, and to potentially bring greater efficiencies to manufacturing and supply chains, to sales and marketing and to the increasingly important customer and patient-focused aspects of the business. Opinions differ, however, on the
    extent that AI will bring down the costs of R&D or find cures, with no drugs as yet discovered and commercialized with AI. The complexities of implementation, meanwhile, are often underplayed amidst the hype. Where will AI add value for pharma and where will it not? Are current algorithms focusing on the right things? Will the pairing of human scientists and AI become the norm in the search for new drugs, and when might we see the first AI developed drug?

    Vipin Gopal, Chief Data and Analytics Officer, Eli Lilly
    Paul Bleicher, CEO, OptumLabs 
    Julie Schiffman, Vice President of Customer Analytics, Pfizer
    Alex Zhavoronkov, CEO, InSilico Medicine

     

    Moderator: Hannah Kuchler, Financial Times

  • 4:10pm
    Panel: Investor forum

    How do investors pick winners in today’s uncertain pharma environment? Where do they see risks and opportunities emerging? How do they view the emerging business models of pharma and their prospects for success?
    Will investors support the industry gradual orientation towards prevention and health management? To what extent are their investment decisions being driven by considerations of the new reimbursement models/? What do investors view as the future of pharma?

    Heather Preston, Managing Partner, Pivotal BioVenture Partners  
    Jeff Schwartz, Managing Director, Bain Capital Life Sciences 

  • 4:40pm
    Closing remarks from the chair
  • 4:45pm
    Networking Drinks Reception

Who Attends

The FT US Pharma & Biotech Summit will be attended by CEOs, CFOs, CTOs CIOs, Head of R&D, Chief Medical Officers, Chief Strategy Officers, Chief Digital Officers, Market Access and Pricing, Chief Business Officers and other senior-level executives in the following sectors:

  • Pharmaceuticals, biotechnology, generic pharmaceutical companies, pharmacies, pharmaceutical wholesalers
  • CROs
  • Healthcare insurers and government payers
  • Pharmaceutical regulators
  • Government healthcare departments and agencies
  • Digital health companies
  • Genomics and personalized medicine experts
  • IT, big data and analytics providers
  • Health economists
  • Diagnostic and medical devices
  • Life Science and Healthcare investment bankers, private equity and venture capitalists
  • Life science and healthcare lawyers and management consultants
  • Patient representatives and health-related NGOs
fallback

Presented by (1)

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of 985,000, three-quarters of which are digital subscriptions. It is part of Nikkei Inc, which provides a broad range of information, news and services for the global business community. 

With the support of (1)

About Life Sciences and Health Care at Deloitte*

Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.

For more information, visit www.deloitte.com/lifesciences or email dttlshc@deloitte.com.

*Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (DTTL), a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity.

Global Clinical Research Partner (1)

ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.

ICON’s award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.

With headquarters in Dublin, Ireland, ICON currently, operates from 93 locations in 37 countries and has approximately 13,650 employees. For further information please visit www.iconplc.com  Follow @iconplc on Twitter.

Lead Sponsors (3)

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
 
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Associate Sponsor (1)

Fees

Ticket

Fee

Standard Summit Ticket 

$1,350

fallback

Venue

Convene - 605 Third Avenue
605 Third Avenue
New York 10158

fallback

NEARBY ACCOMMODATIONS

We have put together a unique Hotel Map that shows hotel deals close to the event venue. To view, click here.

fallback

CONTACT US

Alexsandra Silva
Media Partner and Press Enquiries
Financial Times
Joe Hames
Sponsorship Opportunities
Financial Times
Angela Letinov
Speaking Opportunities
Financial Times
FT Live Delegate Services - EMEA
Delegate Booking and Registration Enquiries
Financial Times